IN2014MN01571A - - Google Patents
Info
- Publication number
- IN2014MN01571A IN2014MN01571A IN1571MUN2014A IN2014MN01571A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A IN 1571MUN2014 A IN1571MUN2014 A IN 1571MUN2014A IN 2014MN01571 A IN2014MN01571 A IN 2014MN01571A
- Authority
- IN
- India
- Prior art keywords
- ocular
- steroid
- pharmaceutical composition
- composition
- umol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597189P | 2012-02-10 | 2012-02-10 | |
| PCT/US2013/025390 WO2013119988A1 (fr) | 2012-02-10 | 2013-02-08 | Compositions pharmaceutiques destinées à réduire les complications liées à un stéroïde oculaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01571A true IN2014MN01571A (fr) | 2015-05-15 |
Family
ID=48948063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1571MUN2014 IN2014MN01571A (fr) | 2012-02-10 | 2013-02-08 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10058616B2 (fr) |
| EP (1) | EP2797601B1 (fr) |
| JP (1) | JP6231995B2 (fr) |
| KR (1) | KR102060210B1 (fr) |
| CN (2) | CN104125830B (fr) |
| AU (1) | AU2013216861B2 (fr) |
| BR (1) | BR112014018393B1 (fr) |
| CA (1) | CA2862055C (fr) |
| CY (1) | CY1120323T1 (fr) |
| DK (1) | DK2797601T3 (fr) |
| ES (1) | ES2673330T3 (fr) |
| HK (1) | HK1201723A1 (fr) |
| IN (1) | IN2014MN01571A (fr) |
| NZ (1) | NZ628124A (fr) |
| PT (1) | PT2797601T (fr) |
| RU (1) | RU2660585C2 (fr) |
| TR (1) | TR201808592T4 (fr) |
| TW (1) | TWI620578B (fr) |
| WO (1) | WO2013119988A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111415822A (zh) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445335A4 (fr) * | 2016-04-19 | 2020-03-04 | Nanyang Technological University | Formulations formant un dépôt sous-conjonctival pour l'administration de médicament au niveau de l'oeil |
| EP3691654A4 (fr) | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | Compositions pharmaceutiques opthalmiques et procédés pour le traitement de maladie de surface oculaire |
| US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| BR112020008046A2 (pt) * | 2017-11-21 | 2020-10-27 | Axerovision, Inc. | composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular |
| SG11202100054YA (en) * | 2018-07-09 | 2021-02-25 | Taiwan Liposome Co Ltd | Methods to reduce complications of intra-articular steroid |
| AU2019417161B2 (en) * | 2018-12-27 | 2023-06-15 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| RU2716429C1 (ru) * | 2019-05-29 | 2020-03-11 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения рецидивирующей эрозии роговицы различного генеза |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
| IL103907A0 (en) * | 1992-11-27 | 1993-04-04 | Pharmos Corp | Ophthalmic compositions |
| CN101229127B (zh) * | 2002-11-26 | 2012-10-10 | 吉里德科学公司 | 脂质体制剂 |
| US9364569B2 (en) | 2003-02-04 | 2016-06-14 | Bracco Suisse S.A. | Ultrasound contrast agents and process for the preparation thereof |
| SI1768657T1 (sl) * | 2004-06-23 | 2009-02-28 | Sirion Terapeutics Inc | Postopki in sestavki za zdravljenje oftalmičnih obolenj z derivati retinila |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| EP1864668B1 (fr) | 2006-06-01 | 2012-11-21 | Novagali Pharma S.A. | Utilisation de promédicaments pour une administration oculaire intravitréenne |
| US20090098145A1 (en) * | 2006-06-22 | 2009-04-16 | Sirion Therapeutics, Inc. | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
| US20080118500A1 (en) | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| EP2255788B1 (fr) * | 2008-02-29 | 2015-07-22 | Nagoya Industrial Science Research Institute | Liposome pour une administration au segment postérieur de l' il et composition pharmaceutique pour une maladie du segment postérieur de l' il |
| CN101502485A (zh) * | 2009-03-20 | 2009-08-12 | 中国药科大学 | 地塞米松眼用纳米立方液晶制剂及其制备方法 |
| CN101926769A (zh) | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | 地塞米松磷酸钠脂质体注射液 |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| BR112012023501A2 (pt) | 2010-03-19 | 2016-05-31 | Massachusetts Inst Technology | vesículas lipídicas multilamelares, composição farmacêutica e método |
| US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2013
- 2013-02-08 US US14/377,211 patent/US10058616B2/en active Active
- 2013-02-08 ES ES13747021.7T patent/ES2673330T3/es active Active
- 2013-02-08 JP JP2014556741A patent/JP6231995B2/ja active Active
- 2013-02-08 TW TW102105245A patent/TWI620578B/zh active
- 2013-02-08 KR KR1020147022121A patent/KR102060210B1/ko active IP Right Grant
- 2013-02-08 IN IN1571MUN2014 patent/IN2014MN01571A/en unknown
- 2013-02-08 CA CA2862055A patent/CA2862055C/fr active Active
- 2013-02-08 BR BR112014018393-7A patent/BR112014018393B1/pt active IP Right Grant
- 2013-02-08 NZ NZ628124A patent/NZ628124A/en unknown
- 2013-02-08 TR TR2018/08592T patent/TR201808592T4/tr unknown
- 2013-02-08 CN CN201380008147.9A patent/CN104125830B/zh active Active
- 2013-02-08 RU RU2014132553A patent/RU2660585C2/ru active
- 2013-02-08 WO PCT/US2013/025390 patent/WO2013119988A1/fr active Application Filing
- 2013-02-08 EP EP13747021.7A patent/EP2797601B1/fr active Active
- 2013-02-08 CN CN201710573136.5A patent/CN107260679B/zh active Active
- 2013-02-08 DK DK13747021.7T patent/DK2797601T3/en active
- 2013-02-08 AU AU2013216861A patent/AU2013216861B2/en active Active
- 2013-02-08 PT PT137470217T patent/PT2797601T/pt unknown
-
2015
- 2015-03-04 HK HK15102213.0A patent/HK1201723A1/xx unknown
-
2018
- 2018-03-06 US US15/913,466 patent/US10350294B2/en active Active
- 2018-06-11 CY CY20181100606T patent/CY1120323T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111415822A (zh) * | 2020-03-05 | 2020-07-14 | 沈阳农业大学 | 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01571A (fr) | ||
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| WO2012021107A3 (fr) | Formulation de liposomes pour l'administration d'un médicament dans l'œil | |
| DOP2012000225A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| AR091006A1 (es) | Formulaciones de testosterona proliposomal | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
| IN2014DN00277A (fr) | ||
| MY156858A (en) | Low-oil pharmaceutical emulsion compositions comprising progestogen | |
| WO2008070463A3 (fr) | Procédés et compositions d'endoxifène | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| RU2014113630A (ru) | Применение омега жирных кислот для лечения заболевания | |
| BR112014015333A8 (pt) | composições lipossomais de clorito ou clorato | |
| MX2021015311A (es) | Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia. | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| CA2854430C (fr) | Corticosteroides liposomaux pour le traitement des affections inflammatoires chez l'homme | |
| NZ718185A (en) | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| MX2017004324A (es) | Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías. | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| MX2016009217A (es) | Inmunoterapia basada en liposomas. | |
| BR112015014137A2 (pt) | unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma |